Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
305.97B
Market cap305.97B
Price-Earnings ratio
17.01
Price-Earnings ratio17.01
Dividend yield
2.65%
Dividend yield2.65%
Average volume
10.33M
Average volume10.33M
High today
$124.00
High today$124.00
Low today
$119.15
Low today$119.15
Open price
$119.68
Open price$119.68
Volume
17.64M
Volume17.64M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 305.97B, Merck(MRK) trades at $123.31. The stock has a price-to-earnings ratio of 17.01 and currently yields dividends of 2.6%.

As of 2026-02-28, Merck(MRK) stock has fluctuated between $119.15 and $124.00. The current price stands at $123.31, placing the stock +3.5% above today's low and -0.6% off the high.

The Merck(MRK)'s current trading volume is 17.64M, compared to an average daily volume of 10.33M.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $125.14 and a 52-week low of $73.31.

MRK News

Simply Wall St 2h
Should Merck’s New STK-012 Keytruda Lung Cancer Combo Strategy Require Action From Investors?

In late February 2026, Synthekine announced a collaboration and supply agreement with Merck to test STK-012 alongside Keytruda and chemotherapy in the ongoing g...

Should Merck’s New STK-012 Keytruda Lung Cancer Combo Strategy Require Action From Investors?
Investor's Business Daily 20h
Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?

Technology Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy? Licensing Merck (MRK) stock, which has climbed 13% in 2026, ticked another box Frida...

Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?
TipRanks 22h
Merck announces results of final analysis of Phase 3 KEYNOTE-B96 trial

Merck (MRK) announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA, Merck’s anti-PD...

Analyst ratings

61%

of 31 ratings
Buy
61.3%
Hold
38.7%
Sell
0%

More MRK News

Simply Wall St 1d
Is It Time To Reassess Merck After Its Strong Multi Year Share Price Run?

If you are wondering whether Merck is still reasonably priced after its run in recent years, this article will walk through what the current share price might b...

Is It Time To Reassess Merck After Its Strong Multi Year Share Price Run?
24/7 Wall St. 2d
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet

Merck Stock Jumps But Reddit Traders Are Getting Cold Feet Quick Read Merck (MRK) faces a December 2028 patent expiration for Keytruda. The drug generates roug...

Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
Simply Wall St 2d
Merck Valuation Check As Keytruda Patent Risk Drives Major Human Health Restructuring

Advertisement Keytruda patent risk puts Merck (MRK) restructuring in focus Merck (MRK) is splitting its human health business into two units, Oncology and Spe...

Merck Valuation Check As Keytruda Patent Risk Drives Major Human Health Restructuring
TipRanks 3d
Merck Animal Health says FDA approves Numelvi for Dogs

Merck (MRK) Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck, announced the U.S. Food and Drug Administrat...

Barron's 3d
Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Biotech and Pharma Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care. In this article MRK GILD Merck said its e...

Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
Simply Wall St 4d
Merck Reorganizes Human Health To Shape Life After Keytruda

Merck (NYSE:MRK) is restructuring its Human Health division into two units: Oncology and Specialty, Pharma & Infectious Diseases. The company has announced new...

Merck Reorganizes Human Health To Shape Life After Keytruda
TipRanks 4d
Merck initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Merck (MRK) with an Outperform rating and $142 price target The firm sees the stock’s investor enthusiasm continuing with near...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.